Previous 10 | Next 10 |
10X Genomics (NASDAQ:TXG) was added as a new short idea at Hedgeye, which sees a deceleration in NIH funding in terms of new funded scientists, a key input for Hedgeye's revenue forecast. Growth peaked in 2020 in rate of change terms, but has been decelerating, according to Hedgeye analy...
PBE is neither suitable for income seekers, nor for long term investors. Despite being a Genomic revolution fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better biotechnology ETFs of similar nature are available in the market. For f...
Today I'll analyze and compare Teladoc (TDOC) and 10x Genomics (TXG) to determine which stock is a better buy. According to a report from Precedence Research , the global telehealth market is forecast to touch $224.8 billion by 2030, up from $40.3 billion in 2020, indicating an annu...
10x Genomics Showcases Robust Innovation Pipeline at Xperience 2022 Event New technology reveals include first data from upcoming Xenium In Situ Analysis Platform PR Newswire PLEASANTON, Calif ,, Feb. 22, 2022 /PRNewswire/ -- 10x Genomics , Inc. (Nasd...
10x Genomics (TXG -14.4%) reached a new 52-week low on Thursday as analysts trimmed their price targets on the stock in reaction to the company’s Q4 2021 earnings release. Despite a strong revenue beat following a ~28% YoY rise in the top line, the company’s quarterly gross marg...
Shares of 10x Genomics (NASDAQ: TXG) have sunk 13.9% as of 10:56 a.m. ET on Thursday. The big decline came after the life sciences company announced its 2021 fourth-quarter and full-year results following market close on Wednesday. 10x Genomics reported fourth-quarter revenue of...
Gainers: Aridis Pharmaceuticals ARDS +12%. Rhythm Pharmaceuticals RYTM +12%. Outset Medical (NASDAQ:OM) +10%. Masimo (NASDAQ:MASI) +8%. Vivos Therapeutics (NASDAQ:VVOS) +7%. Losers: 10x Genomics (NASDAQ:TXG) -16%. iSpecimen ISPC -10%. Poseida ...
Amplitude (NASDAQ:AMPL) -41% on Q4 earnings release. Fastly (NYSE:FSLY) -30% on Q4 earnings release. 10x Genomics (NASDAQ:TXG) -23% on Q4 earnings release. Matterport (NASDAQ:MTTR) -19% on Q4 earnings release. AppLovin (NASDAQ:APP) -...
On Feb. 15, institutional investment managers with more than $100 million AUM had to disclose their positions at the end of Q4 2021. I curated a list of some of the best-performing hedge funds and looked into their holdings at the end of December 2021. This list is particularly ti...
10x Genomics, Inc. (TXG) Q4 2021 Earnings Conference Call February 16, 2022, 04:30 PM ET Company Participants Eric Jaschke - Director of IR and Strategic Finance Serge Saxonov - CEO and Co-Founder Justin McAnear - CFO Conference Call Participants Tycho Peterson - JPMorgan Derik De Bruin - Ban...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...